TP53 and myelodysplastic syndrome: Magrolimab has shown encouraging clinical activity in AML and higher-risk MDS (HR-MDS) when combined with azacitidine, especially in patients harboring a TP53 mutation, providing the basis for several ongoing randomized clinical trials [13,14].